Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes Clinical Trial

Official title:

A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High Risk Myelodysplastic Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04402541
• Other study ID #: CTX-001
• Status: Completed
• Phase: Phase 1
• Start date: June 8, 2020
• Est. completion date: July 23, 2023

Study information

• Verified date: August 2023
• Source: Cleave Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, open-label Phase 1 study of orally administered CB-5339 in participants with R/R AML or participants with R/R intermediate- to high-risk MDS.

Description:

This is a multicenter, open-label Phase 1 study of orally administered CB-5339 in participants with R/R AML or participants with R/R intermediate- to high-risk MDS. The study will include two parts:1) a Dose Escalation phase in participants with R/R AML, or R/R intermediate- to high-risk MDS and 2) a Dose Expansion phase in participants with R/R AML for whom there is no standard of care therapy available that is likely to lead to disease remission. Additional cohorts for participants with R/R intermediate- to high-risk MDS following hypomethylating agents or other AML cohorts may be added at a later time.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: July 23, 2023
• Est. primary completion date: July 23, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female and = 18 years of age at the time of signing the consent form

2. One of the following advanced hematologic malignancies including:

• Relapsed or refractory AML as defined by 2016 WHO criteria and are not candidates for curative therapies such as allogeneic hematopoietic cell transplant or for whom there is no standard of care therapy available that is likely to lead to disease remission according the investigator
• MDS high-very high risk by the revised international scoring system for evaluating prognosis in myelodysplastic syndromes that is recurrent or refractory or the participant is intolerant to established therapy known to provide clinical benefit for their condition (e.g., relapsed following treatment with hypomethylating agent or lack of response after > 4 cycles), according to treating physician. Potential participants who meet the criteria for intermediate risk may be considered with approval by the medical monitor if the participant has severe cytopenia(s) and/or elevated bone marrow blast counts.

3. Adequate organ function defined as:

• Serum creatinine =1.5 mg/dL or an estimated glomerular filtration rate of =60 mL/min as calculated by the Cockcroft-Gault glomerular filtration rate equation
• Total bilirubin = 1.5 × the upper limit of normal (ULN) unless considered due to Gilbert's disease or leukemic disease
• Aspartate aminotransferase (AST) =3 × the ULN; alanine aminotransferase (ALT) =3 × the ULN. Levels of AST and/or ALT =5 × the ULN may be acceptable for participants with known leukemic involvement of the liver after discussion with the study medical monitor

4. Eastern Cooperative Oncology Group (ECOG) performance status =2.

5. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If of childbearing potential, agree to use an effective barrier method of birth control (i.e., latex condom, diaphragm, cervical cap, etc.) to avoid pregnancy during the study and 90 days after the last dose of CB-5339. Female participants of childbearing potential need a negative serum or urine pregnancy test within 7 days of study enrollment. Non-childbearing is defined as = 1 year postmenopausal or surgically sterilized

6. Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol

Exclusion Criteria:

1. Acute promyelocytic leukemia with t(15;17)(q22;q12); or abnormal promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA).

2. Participants with clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if there is a clinical suspicion of CNS involvement by leukemia during screening.

3. Participants with immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.

4. Concomitant malignancy, requiring active treatment, except for basal-cell or squamous cell carcinoma of the skin, carcinoma-in-situ of the uterine cervix, or localized prostate cancer.

• Adjuvant therapy for breast cancer or prostate cancer is allowed.

5. Active, uncontrolled, systemic infection or severe localized infection during screening or prior to Cycle 1 Day 1 (C1D1; unless considered due to tumor by the investigator).

• Note, participants receiving prophylactic anti-infectives are allowed on study.

6. Known human immunodeficiency virus (HIV) infection with CD4+ T cell counts <350 cells/µL, initiation of antiretroviral therapy within 4 weeks before C1D1, or acquired immunodeficiency syndrome (AIDS)-related infection within 12 months before C1D1.

7. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection with viral load above the limit of quantification

8. Major cardiac abnormalities as defined but not limited to the following: uncontrolled angina or unstable life-threatening arrhythmias, history of myocardial infarction within 12 weeks prior to Baseline, Class 3 or higher New York Heart Association (NYHA) congestive heart failure, or left ventricular ejection fraction (LVEF) <45% as measured by echocardiogram (ECHO) within 28 days of C1D1

9. Persistent (3 consecutive ECGs performed =5 minutes apart) prolongation of the corrected QT interval by Fredericia's method (QTcF) to > 480 msec

10. Gastrointestinal conditions that may interfere with the absorption of orally-administered drugs including but not limited to short gut syndrome, gastroparesis, inflammatory bowel disease, or acute pancreatitis.

11. Any other severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or CB-5339 administration, may interfere with the informed consent process and/or with compliance with the requirements of the study, may interfere with the interpretation of the study results and, in the Investigator's opinion, or would make the participant inappropriate for entry into this study

12. A condition that is expected to require concomitant use of any medication listed as prohibited while on study.

13. Known hypersensitivity to any components of CB-5339.

14. Use of chemotherapy (except hydroxyurea), radiation or monoclonal antibodies within 14 days or 5 half-lives for small molecule inhibitors prior to first dose of CB-5339

15. Participants who have undergone a hematopoietic cell transplant (HCT) within 100 days of the first dose of CB-5339, or participants on immunosuppressive therapy post-HCT at the time of screening, use of calcineurin inhibitors within 4 weeks prior to first dose of CB-5339, or with clinically significant graft-versus-host disease (GVHD).

• Note: The use of topical steroids or <10mg oral prednisone for ongoing skin GVHD is permitted.

16. Major surgery within 4 weeks prior to first dose of CB-5339. Participant must have recovered from surgery and be without current complications of infection or dehiscence

17. Enrollment in other clinical trials unless approved by Medical Monitor

Related Conditions & MeSH terms

• Acute Myeloid Leukemia, in Relapse
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Drug:
• CB-5339
25mg and 75mg capsules

Locations

Country	Name	City	State
Australia	St. Vincent Hospital, Sydney, NSW	Darlinghurst	New South Wales
Australia	Epworth Healthcare	Melbourne	Victoria
Australia	Haematology Clinical Trials Unit, Royal Perth Hospital	Perth	Western Australia
United States	Cleveland Clinic, Case Comprehensive Cancer Center	Cleveland	Ohio
United States	KU Clinical Research Center	Fairway	Kansas
United States	Saint Francis Hospital Cancer Center	Greenville	North Carolina
United States	MD Anderson Cancer Cancer	Houston	Texas
United States	USC Norris Comprehensive Cancer Center	Los Angeles	California
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Weill Cornel Medical Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Cleave Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).		28 Days
Primary	Define the MTD and/or RP2D and schedule for CB-5339	Incidence and nature of DLTs with CB-5339 monotherapy for MTD determination. All available safety, efficacy and PK, for RP2D determination	28 Days
Secondary	Peak plasma concentration (Cmax)		Day 1 and Day 4
Secondary	Time to reach peak plasma concentration (Tmax)		Day 1 and Day 4
Secondary	Area under the plasma concentration time curve (AUC0-t)		Day 1 and Day 4
Secondary	Elimination half-life (t½)		Day 1 and Day 4
Secondary	Accumulation ratio		Day 1 and Day 4
Secondary	Antitumor effects	CR/CRi rate at the RP2D in participants with R/R AML, as assessed by the investigator, based on 2017 ELN response criteria.; Objective response rate (ORR) at the RP2D in participants with R/R AML, as assessed by the investigator based on 2017 ELN response criteria.; DoCR in participants with R/R AML who attain CR or CRi	End of each cycle (cycle is 28 days)